Data Year:

For its 2025 fiscal year, ORTHOPEDIATRICS CORP, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In MFG Durable industry
Fred L. Hite
Chief Operating Officer and Chief Financial Officer
Total Compensation $2,397,186 View details Pay Rank By Title In MFG Durable industry #311 View more
Daniel J. Gerritzen
Executive Vice President (Legal), General Counsel, and Secretary
Total Compensation $1,497,064 View details Pay Rank By Title In MFG Durable industry #130 View more
David R. Bailey
President and Chief Executive Officer
Total Compensation $3,331,481 View details Pay Rank By Title In MFG Durable industry #497 View more
Gregory A. Odle
President of Scoliosis
Total Compensation $1,498,184 View details Pay Rank By Title In MFG Durable industry #147 View more
Joseph W. Hauser
President of Trauma, Deformity and OPSB
Total Compensation $1,974,862 View details Pay Rank By Title In MFG Durable industry #109 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at ORTHOPEDIATRICS CORP as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ORTHOPEDIATRICS CORP income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ORTHOPEDIATRICS CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Fred L. Hite
Chief Operating Officer and Chief Financial Officer
Total Cash $794,569 Equity $1,588,617 Other $14,000 $2,397,186
Daniel J. Gerritzen
Executive Vice President (Legal), General Counsel, and Secretary
Total Cash $511,757 Equity $972,427 Other $12,880 $1,497,064
David R. Bailey
President and Chief Executive Officer
Total Cash $872,281 Equity $2,445,200 Other $14,000 $3,331,481
Gregory A. Odle
President of Scoliosis
Total Cash $511,757 Equity $972,427 Other $14,000 $1,498,184
Joseph W. Hauser
President of Trauma, Deformity and OPSB
Total Cash $652,463 Equity $1,308,399 Other $14,000 $1,974,862
For its 2025 fiscal year, ORTHOPEDIATRICS CORP, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
David R. Bailey CEO Pay $3,331,481 Median Employee Pay $102,800 CEO Pay Ratio 32:1
For its 2024 fiscal year, ORTHOPEDIATRICS CORP, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Bryan W. Hughes Total Cash $190,000
David R. Pelizzon Total Cash $180,000
George Dyer Total Cash $180,000
Harald Ruf Total Cash $180,000
Jimmy D. McDonald Total Cash $180,000
Marie C. Infante Total Cash $185,000
Mark Throdahl Total Cash $45,000
Samuel D. Riccitelli Total Cash $180,000
Terry D. Schlotterback Total Cash $185,000
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.